GlaxoSmithKline CEO on spinoff of consumer health-care business

GlaxoSmithKline's stock rose 3.5% in the premarket Wednesday after it detailed plans to spin out its consumer health-care business into a separate company. Glaxo will eventually receive an $11 billion payment from the new company. GlaxoSmithKline CEO Emma Walmsley joined "Squawk Box" on Wednesday to discuss.
Wed, Jun 23 20218:43 AM EDT